India rejects Novartis patent bid for cancer drug


A court in India has dismissed a patent bid by the pharmaceutical company Novartis.

The Swiss company wanted to protect its cancer drug Glivec.

Healthcare activists say the ruling ensures that cheaper generic versions of the drug will remain accessible in a country where many patented drugs are too costly for most people.

Shilpa Kannan reports.

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.